glp-1 and breast cancer risk drugs cut by 30%? Not so fast Breast cancer: GLP-1 use may

Participants were followed for up to five years after treatment initiation, with follow-up ending at drug discontinuation, switching, death, or loss to follow-up

95% CI: 0.100.50) and 1324 months after treatment initiation compared with pretreatment

In human research contexts, doses ranging from 20 to 100 micrograms per day have been discussed in gray literature, but no published human dose-finding trial exists

Is Carnitine a stimulant

Research involving cagrilintide is conducted under strict ethical and regulatory oversight, ensuring compliance with scientific standards and data integrity

Lipid peroxidation results in the formation of lipid peroxides and various toxic byproducts, which lead to a cascade of cellular damage, ultimately impairing sperm function